June 4, 2018 by Chain Drug Review
retail
Issue 06-04-2018, Opinion

NEW YORK — With e-commerce capturing a growing slice of the retail pie, the future of the physical store becomes a more urgent question. Coresight Research tackled the issue in the third and final installment of its “Retail Reworked” series, focusing on areas of opportunity for brick-and-mortar retailers in a time when more and more
June 4, 2018 by Jeffrey Woldt
prescription drug prices, President Donald Trump
Issue 06-04-2018, Opinion

President Trump has unveiled the administration’s much anticipated plan to reduce pharmaceutical prices. Speaking in the White House Rose Garden last month, the president touted what he characterized as “the most sweeping action in history to lower the prices of prescription drugs for the American people.” Long on rhetoric and short on specifics, the initiative
June 4, 2018 by Chain Drug Review
Kroger, Ocado
Issue 06-04-2018

CINCINNATI — Kroger Co. has upped its investment in U.K. digital grocer Ocado as part of an exclusive agreement that will bring Ocado’s automated fulfillment network to the United States to bolster Kroger’s home delivery capabilities. Kroger currently offers a click-and-collect system at more than 1,000 stores, and it has partnered with Instacart and other
June 4, 2018 by Chain Drug Review
CVS, opioid abuse
Issue 06-04-2018

NEW YORK — As the epidemic of opioid abuse continues to escalate in America, corporations and other organizations are ramping up their efforts to fight the problem. Rite Aid Corp., for instance, recently announced that DisposeRx, a first-of-its-kind opioid disposal solution, is now available at all of its more than 2,500 pharmacies in locations across
June 4, 2018 by Chain Drug Review
Issue 06-04-2018

WOONSOCKET, R.I. — Two CVS Health executives were in the spotlight last month at events discussing the new challenges facing the health care industry. Tom Moriarty, chief policy and external affairs officer and general counsel at CVS Health, was interviewed by Patrick Steel, chief executive officer of Politico, to discuss the chain’s commitment to addressing
June 4, 2018 by Chain Drug Review
automation, Discount Drug Mart
Issue 06-04-2018

MEDINA, Ohio — Discount Drug Mart and McKesson High Volume Solutions (HVS) have entered into a pharmacy automation agreement that calls for McKesson HVS to provide the retail pharmacy operator with a dispensing automation platform for a central fill pharmacy in Avon Lake, Ohio. With value-based reimbursement becoming increasingly important, Discount Drug Mart believes the
June 4, 2018 by Chain Drug Review
Albertsons-Rite Aid merger
Issue 06-04-2018

BOISE, Idaho — Albertsons Cos. and Rite Aid Corp. hosted a joint analyst event last month to discuss the strategic and financial benefits of the proposed merger transaction between the two companies. Announced in late February, the merger will join the nation’s second-largest supermarket operator with its third-largest drug chain. The combined company will generate
June 4, 2018 by Chain Drug Review
Brian Griffin, Diplomat
Issue 06-04-2018

FLINT, Mich. — The board of directors of Diplomat Pharmacy has appointed Brian Griffin board chairman and chief executive officer, effective June 4, the company announced last month. Griffin recently resigned as the executive vice president and CEO of IngenioRx, the pharmacy benefit manager of Anthem Inc. “We are pleased to welcome Brian to the
June 4, 2018 by Chain Drug Review
Stefano Pessina, Walgreens, WBA
Issue 06-04-2018

NEW YORK — Walgreens Boots Alliance executive vice chairman and chief executive officer Stefano Pessina urged analysts not to think they can see the future of Walgreens simply by visiting the company’s new pilot stores in Gainesville, Fla. “Let’s be clear,” Pessina said during a sell-side analyst event in New York last month. “Gainesville today
June 4, 2018 by Chain Drug Review
chain drug retailers, drug prices
Issue 06-04-2018

NEW YORK — Chain drug retailers reacted favorably to President Trump’s drug price cutting plan; branded pharmaceutical manufacturers less so. Walgreens, which had pharmacists at the White House for the president’s announcement of the proposal, said in a statement the blueprint “is a positive step forward in addressing the issue of rising drug prices.” The
June 4, 2018 by Chain Drug Review
Donald Trump, drug prices
Issue 06-04-2018

WASHINGTON — The White House last month steered clear of extreme measures in issuing a plan to cut drug prices. While President Donald Trump called the proposal “the most sweeping action in history to lower the price of prescription drugs for the American people,” the plan left industry stakeholders relieved. Pharmaceutical company stocks even gained